	Application Number		10526365		
	Filing Date		2005-11-15		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor	Curtis	es .		
	Art Unit		1633		
	Examiner Name	Popa,	, Ileana		
	Attorney Docket Number	er	56029-53712		

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date  Name of Patentee or Applica of cited Document				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5824538		1998-10	)-20	Branstrom et a					
	2	5877159		1999-03	3-02	Powell et al.					
If you wis	h to ac	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication  Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	If you wish to add additional U.S. Published Application citation information please click the Add button. Add										
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j		Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document		here Rel	or Relevant	T5
	1	WO96/40947	wo			1996-12-19	Washington University				
	2	WO00/04920	WO			2000-02-03	Megan Health, Inc				
		·					1				

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10526365		
Filing Date		2005-11-15		
First Named Inventor Curtis		s		
Art Unit		1633		
Examiner Name Popa,		lleana		
Attorney Docket Number		56029-53712		

If you wisl	n to ac	dd additional Foreign Patent Document citation information please click the Add button Add					
		NON-PATENT LITERATURE DOCUMENTS Remove					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	<b>T</b> 5				
	1	Frey et al., Bacteremia Associated with Live Attenuated x8110 Salmonella enterica serovar Typhi ISP1820 in Healthy Adult Volunteers, Clinical Immunology, Vol. 101, No. 1, pp. 32-37 (October 2001)					
	Guzman et al., Tight Regulation, Modulation, and High-Level Expression by Vectors Containing the Arabinose PBAD Promotor, Journal of Bacteriology, Vol. 177, No. 14, pp. 4121-4130 (July 1995)						
	3	Hollingshead et al., Diversity of PspA: Mosaic Genes and Evidence for Past Recombinant in Streptococcus pneumoniae, Infection and Immunity, Vol. 68, No. 10, pp. 5889-5900 (October 2000)					
	4	Kang et al., Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization, FEMS Immunology and Medical Microbiology, 37 pp. 99-104 (March 2003)					
	5	Kang et al., Immune Responses to Recombinant Pneumococcal PspA Antigen Delivered by Live Attenuated Salmonella enterica Serovar Typhimurium Vaccine, Infection and Immunity, Vol. 70, No. 4, pp. 1739-1749 (April 2002)					
	6	Kong et al., Construction and Application of Host-Vector Systems for DNA Vaccine Vector Delivery, Abstracts of the General Meeting of the American Society for Microbiology, Z-016, pp. 677 (May 2003)					
	7	Kong et al., Regulated Bacterial Lysis for Antigen Release, Abstracts of the General Meeting of the American Society for Microbiology, E-031, pp. 255 (May 2003)					
	8	Nakayama et al., Construction of an ASD+ Expression-Cloning Vector: Stable Maintenance and High Level Expression of Cloned Genes in a Salmonella Vaccine Strain, Bio/Technology, Vol. 6, pp. 693-697 (June 1988)					
	9	Nayak, et al., A Live Recombinant Avirulent Oral Salmonella Vaccine Expressing Pneumococcal Surface Protein A Induces Protective Responses against Streptococcus pneumoniae, Infection and Immunity, Vol. 66, No. 8, pp. 3744-3751 (August 1998)					

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number Filing Date		10526365
		2005-11-15
First Named Inventor Curtis		ss
Art Unit		1633
Examiner Name Popa,		, Ileana
Attorney Docket Number		56029-53712

	10	Schodel et al., Salmonellae as Oral Vaccine Carriers, Dev. Biol. Stand., Vol. 84, No. 188, pp. 245-253 (1995)						
	11	Sizemore et al., Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization, Science, Vol. 270, pp. 299-302 (October 1995)						
	12	Sizemore et al., Attenuated bacteria as a DNA Delivery vehicle for DNA-mediated immunization, Vaccine, Vol. 15, No. 8, pp. 804-807 (1997)						
	Formal et al., Construction of a Potential Bivalent Vaccine Strain: Introduction of Shigella sonnei Form I Antigen Genes into the galE Salmonella typhi Ty21a Thphoid Vaccine Strain, Infection and Immunity, Vol. 34, No. 3, pp. 746-750 (December 1981)							
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	er Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
<sup>1</sup> See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.								